



Cincinnati, Ohio (N=193)

Figure A. Age of GISP participants, in years, 2010




Cincinnati, Ohio (N=193)

Figure B. Race/ethnicity of GISP participants, 2010




Cincinnati, Ohio

Figure C. Percentage of GISP participants identifying as men who have sex with men, 2000-2010




Cincinnati, Ohio (N=193)

Figure D. Drugs used to treat gonorrhea among GISP participants, 2010





Cincinnati, Ohio (N=193)

Figure E. Drugs used to treat *Chlamydia trachomatis* infection among GISP participants, 2010




Cincinnati, Ohio (N=193)

Figure F. Resistance to penicillin, tetracycline, and ciprofloxacin among GISP isolates, 2010




Cincinnati, Ohio

Figure G. Distribution of Minimum Inhibitory Concentrations (MICs) to ceftriaxone among GISP isolates, 2006-2010



Cincinnati, Ohio


Figure H. Distribution of Minimum Inhibitory Concentrations (MICs) to cefixime among GISP isolates, 2006 and 2009-2010



NOTE: Isolates were not tested for cefixime susceptibility in 2007 and 2008.

Cincinnati, Ohio

Figure I. Intermediate resistance and resistance to ciprofloxacin among GISP isolates, 1990-2010



Note: Susceptibility to ciprofloxacin first measured in 1990.

Cincinnati, Ohio

Figure J. Distribution of Minimum Inhibitory Concentrations (MICs) to azithromycin among GISP isolates, 2006-2010

